Solid Biosciences has announced key updates from its clinical development pipeline, highlighting the administration of SGT-003 to four patients in the INSPIRE DUCHENNE trial for Duchenne muscular ...

business plans and objectives on the clinical development of clinical and preclinical pipeline, including the therapeutic potential, clinical benefits and safety thereof, Sanofi’s expansion of ...

Xencor Inc . (NASDAQ:XNCR), a biopharmaceutical company specializing in innovative therapies for immunology and oncology, ...

Pipeline Updates and 2025 Anticipated Milestones ... program through the completion of Phase 1 clinical development, which will be funded by Lilly. Lilly will then be responsible for subsequent ...

The phage therapy market is experiencing significant growth due to the increasing prevalence of antibiotic-resistant infections and the growing interest in alternative treatments. Advances in ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge the company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

This valuation reflects both the potential of its pipeline and the inherent risks associated with clinical-stage drug development. The biotechnology sector, particularly in oncology and immunology ...

ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...

Eleva, a pioneer in unlocking biologics based on a breakthrough manufacturing platform, and 3PBIOVIAN, a contract development ...